Published by: Joseph Kruger, Seeking Alpha |
Date: 17 January 2010
At the 28th annual JP Morgan Healthcare conference, which ran from January 11- January 14th 2010, there were more than 300 companies represented, making their presentations to more than 6000 public and private equity and venture capital investors. There was considerable enthusiasm for the sector this past week; it seemed like every biotech company rallied and closed the week up. But what will happen after the JP Morgan Healthcare Conference? Was the activity the last couple weeks just due to short term investor enthusiasm?
|
Published by: Marcel Wijma |
Date: 10 January 2010
One of the best performing European biotech companies in 2009 was Swedish biotech company Active Biotech. With a performance of more than 200% the stock was one of the top 3 best performing Biotech companies. And also in 2010 the company seems to continue its winning streak with a YTD performance of already 35%. What is the story behind this amazing performance.
|
Published by: |
Date: 22 October 2009
They say aging is one of the few certain things in life. But it turns out that they were wrong. In recent years gerontologists have overturned much of the conventional wisdom about getting old. Aging is not the simple result of the passage of time. According to a provocative new view, it is actually something our own bodies create, a side effect of the essential inflammatory system that protects us against infectious disease. As we fight off invaders, we inflict massive collateral damage on ourselves, poisoning our own organs and breaking down our own tissues. We are our own worst enemy.
|
Published by: Marcel Wijma |
Date: 22 October 2009
Vanaf morgen kunnen we een nieuw aandeel op Euronext in de sector Life Sciences verwelkomen. Het Nederlandse bedrijf Cryo-Save maakt haar opwachting om toe te treden tot het selecte gezelschap van winstgevende bedrijven in deze sector.
|
Published by: Marcel Wijma |
Date: 07 October 2009
Na de deal met JNJ heeft Crucell de beschikking over een substantiele hoeveelheid geld. Daarmee zullen zeker overnames gedaan worden. Wie staan er in het vizier?
|
Published by: Indie Research |
Date: 06 September 2009
Investors are placing final bets on upcoming late-stage trial data from Osiris Therapeutics. The company's Prochymal is being tested as a treatment for GvHD, a potentially deadly complication of bone marrow transfusions
|
Published by: Zacks |
Date: 06 September 2009
Genomic Health is doing good business with its breast cancer test Oncotype DX. More surgeons ask for the test before performing surgery or biopsy. Genomic Health is a strong competitor of Dutch based Agendia
|
Published by: Motley Fool |
Date: 06 September 2009
Biogen Idec (Nasdaq: BIIB) announced that it's willing to buy Facet Biotech (Nasdaq: FACT) for $14.50 per share. Trading in shares was halted, but once it began again, the price rose quickly. In fact, late afternoon prices seem to indicate that investors hope that Facet's management changes its initial "no" to a "yes."
|
Published by: Marcel Wijma |
Date: 06 September 2009
Most big pharma companies face the increasing problem of expiring patents. This will put strong pressure on revenues in the next few years. Biotech is ready to provide with solutions.
|
Published by: Marcel Wijma |
Date: 28 August 2009
At first the share price of Danish/Dutch biotech company Genmab (GEN CO) took a nosedive after the release of disappointing results with its drug Arzerra in refractory NHL patients. The latest results show a completely different picture. What to do?
|